Seletracetam (ucb 44212) is a high affinity for the synaptic vesicle protein 2A (SV2A) than levetiracetam with 10-fold, exhibits anticonvulsant properties in animal models of epilepsy.

Secdin is a small-molecule inhibitor of Arabidopsis thaliana ADP-ribosylation factor (ARF)-guanine nucleotide exchange factors (GEFs), impaires both hypocotyl and root growth in young Arabidopsis seedlings with IC50 of 4 uM.

SC-919 (SC919) is a potent, selective inhibitor of IP6K (Inositol hexakisphosphate kinase) with IC50 of <5.2, <3.8 and 0.65 nM for human IP6K1/2/3, respectively.

SB-U015 is a MitoQ derivative and tumor necrosis factor receptor-associated protein 1 (TRAP1) inhibitor.

SBL-105 (SBL105) is a potent, selective DHODH inhibitor with IC50 of 48.48 nM (rh DHODH).

SBI-0802936 (SBI 0802936) is an analog of SMIP004-7, inhibits NADH:ubiquinone oxidoreductase (complex I), 4-6 times more potently than SMIP004-7, acting in the same uncompetitive fashion as SMIP004-7.

SB1501 (SB 1501) is a bioactive compound that reduces fat accumulation by elevating mitochondrial biogenesis and fatty acid oxidation via the PGC-1α-UCP1 pathway, shows anti-obesity effects in vivo.

SAN4825 is a selective small-molecule inhibitor of cardiac ADP-ribosyl cyclase (ADPR cyclase) with IC50 of 0.13 uM.

SACLAC is an α-chloroamide ceramide analog that binds irreversibly to acid ceramidase (ASAH1), significantly reduces the viability of AML cells (EC50=3 uM) across 30 human AML cell lines.

S202 is a potent, selective and brain-penetrant small molecule inhibitor of ceramide galactosyltransferase (CGT) with IC50 of 15 nM in the cell-lysate assays and 3.6 nM in intact-cell assays.

RX-207 (RX207) is a small molecule inhibitor of protein binding to glycosaminoglycans (SMIGs), inhibits protein binding to glycosaminoglycans (GAGs), inhibits inflammatory neutrophil adhesion and activity in vitro and in vivo.

RX-105 (RX105) is a small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs) with anti-inflammatory properties, binds directly to glycosaminoglycans (GAGs).

RU-NT-206 is a small molecule inhibitor targeting the P-stalk binding pocket of ricin toxin A subunit (RTA) with IC50 of 7 uM, inhibits catalytic activity and protects cells against ricin and Stx2 holotoxins.

RTI-263 (SerPheLysAsn-NH2) is a potent, selective tetrapeptide neuropeptide S receptor (NPSR, GPR154) biased agonist with EC50 of 3.02 nM for hNPSR calcium mobilization.

RPI-194 is a novel troponin activator that binds to cardiac/slow skeletal muscle troponin, binds to cardiac troponin with KD of 24 uM, stabilizing the activated complex between troponin C and the switch region of troponin I.

RPE65-61 ((±)-RPE65-61) is a selective, non-retinoid and uncompetitive inhibitor of RPE65 (a key enzyme in the visual cycle), inhibits the retinol isomerase activity of RPE65 in vitro with IC50 of 80 nM.

Ro 48-8071 is a potent 2,3-oxidosqualene cyclase (OSC) inhibitor with IC50 of 6.5 nM.

RG100204 is a novel selective, small molecule inhibitor of the neutral solute channel Aquaporin 9 (AQP9), inhibits AQP9 water permeability (IC50=110 nM) and AQP9 glycerol permeability (IC50=76 nM).

RF03176 is a selective AQP9 inhibitor with IC50 of 1.3 uM (inhibition of CHO-AQP9 cell water permeability).

RECTAS is a small molecule splice modulator that corrects aberrant splicing of familial dysautonomia (FD), promotes exon 20 inclusion of IKBKAP pre-mRNA and expression of IKAP.

RBS-10 is a small molecule that shows preferential cytotoxicity against cells pan-resistant to degraders, acts as a prodrug bioactivated by the oxidoreductase enzyme NQO1.

RA 5557 is a brain-penetrant, selective, oral UGT8 inhibitor, inhibits galactosylceramide biosynthesis.

R805 is a small molecule modulator of gp130 receptor pro-inflammatory signaling, targets a signaling tyrosine 814 (Y814) within gp130, modulates gp130 Y814 upstream of the SRC and MAPK circuit, elicits a protective effect on tissues after injury.

QP5038 is a potent inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with IC50 of 3.8 nM, shows promising in vitro and in vivo anti-tumor efficacies.

PXS-6302 (PXS6302) is a potent, irreversible pan-lysyl oxidase (pan-LOX) inhibitor with IC50 of 3.7 uM and 3.4/0.4/1.5/0.3 uM for bovine (aorta) LOX and rh LOXL1/2/3/4, respectively.

PXS-5505 dihydrochloride monohydrate is an orally available, small-molecule, irreversible inhibitor of all lysyl oxidases (pan-LOX) family members, with potential antifibrotic activity.

PXS-5129A is the pro-drug form of PXS-5120A, a potent, selective, irreversible inhibitor of Lysyl oxidase-like 2 (LOXL2).

PTI-125 (Simufilam, Sumifilam) is a small molecule targeting scaffolding protein filamin A (FLNA), preferentially binds altered FLNA and restores its native conformation.

PT91 is a small-molecule GPR27 (SREB1) agonist with pEC50 of 6.15 (human GPR27) in β-arrestin 2 recruitment-based firefly luciferase complementation assay, Emax=100%.

PSB-KK-1415 is a selective GPR18 agonist with EC50 of 19.1 nM (hGPR18) in β-arrestin recruitment assays, shows no activity against GPR55.